This could become the next revolutionary antiviral medicine.
| | 
A First-In-Class, Broad-Spectrum Antiviral Agent Intending to Revolutionize Treatment of Viral Infections Including RSV, COVID, Influenzas and More... No matter how much a virus changes in the field, it uses the same "landing sites" in the host body to gain access to cells, attach to, and then fuse into the cells, causing an infection. A drug using the same landing sites and acting as a "decoy" would remain effective against the virus even as the virus changes, because the host side does not change. NanoViricides, Inc. (NYSE: NNVC) is an emerging NYSE company that has this kind of an answer: NV-387, which is designed to employ such advanced "host-mimetic" technology, built into the nanoviricide™ nanomedicine that is further designed to "look like a cell" to the virus. In contrast, vaccines, antibodies and small chemical drugs all lose their effectiveness as the virus changes in the field. The virus is constantly changing due to various natural mechanisms such as mutations, recombinations, and/or re-assortments that are native to the virus lifecycle. Over 90% of human pathogenic viruses are known to use one or more "landing sites" that are in the Sulfated Proteoglycans ("SPG") family. A successful host-mimetic nanoviricide drug using SPG as the key feature to attract viruses could theoretically be able to attack most if not all such viruses. NV-387 is designed to mimic SPG and attack the virus as a cell-mimicking decoy. The company has accumulated substantial evidence that in lethal viral infection animal studies and NV-387 demonstrated strong antiviral activity against a range of different virus families, exceeding or matching the activity of known approved drug agents! NV-387 was substantially superior to remdesivir in coronavirus infections, using a model for SARS-CoV-2 (COVID) virus. NanoViricides, Inc. (NYSE: NNVC) believes that NV-387 continues to be one of the most active antiviral drugs against multiple coronaviruses, and that it is a viable clinical candidate for drug development to treat COVID, Long COVID, as well as potentially MERS, SARS, and seasonal coronavirus infections. Learn more about how NNVC's NV-387 may become the next revolutionary antiviral medicine. Regards,
Interactive Offers, LLC | | | | | | This is a PAID ADVERTISEMENT provided to customers of Schaeffer's Investment Research. Although we have sent you this email, Schaeffer's does not specifically endorse this product nor is it responsible for the content of this advertisement. Furthermore, we make no guarantee or warranty about what is advertised above. To stop receiving these emails, unsubscribe.
Schaeffer's Investment Research
5151 Pfeiffer Road, Suite 450
Cincinnati, Ohio 45242
| | |
No comments:
Post a Comment